Cassette-based presentation of SIV epitopes with recombinant gas vesicles from halophilic archaea

被引:29
作者
Stuart, ES [1 ]
Morshed, F
Sremac, M
DasSarma, S
机构
[1] Univ Massachusetts, Dept Microbiol, Amherst, MA 01003 USA
[2] Genzyme Corp, Cambridge, MA 02139 USA
[3] Univ Maryland, Ctr Marine Biotechnol, Inst Biotechnol, Baltimore, MD 21202 USA
关键词
SIV; HIV; archaea; epitope display; recombinant cassettes;
D O I
10.1016/j.jbiotec.2004.01.005
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
In earlier studies we demonstrated recombinant gas vesicles from Halobacterium sp. NRC-1, expressing a model six amino acid insert, or native vesicles displaying chemically coupled TNP, each were immunogenic, and antigenic. Long-lived responses displaying immunologic memory were elicited without exogenous adjuvant. Here we report the generation and expression of cassettes containing SIV derived DNA. The results indicate a cassette-based display/delivery system derived from recombinant halobacterial gas vesicle genes is highly feasible. Data specifically support four conclusions: (i) Recombinants carrying up to 705 bp of SIV DNA inserted into the gvpC gene form functional gas vesicles; (ii) SIV peptides contained as part of the expressed recombinant, surface exposed GvpC protein are recognized by antibody elicited in monkeys exposed to native SIV in vivo; (iii) in the absence of adjuvant, mice immunized with the recombinant gas vesicle (r-GV) preparations mount a solid, titratable antibody response to the test SIV insert that is long lived and exhibits immunologic memory; (iv) recombinant organelles, created through the generation of cassettes encoding epitopes inserted into the gvpC DNA, can be used to construct a multiepitope display (MED) library, a potentially cost effective vehicle to express and deliver peptides of SIV, HIV or other pathogens. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:225 / 237
页数:13
相关论文
共 44 条
[31]  
Robb FT, 1995, ARCHAEA LAB MANUAL
[32]  
Ruprecht RM, 2000, J HUMAN VIROL, V3, P88
[33]  
Russell MW, 1999, AM J REPROD IMMUNOL, V42, P58
[34]   Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection [J].
Salmon-Céron, D ;
Excler, JL ;
Finkielsztein, L ;
Autran, B ;
Gluckman, JC ;
Sicard, D ;
Matthews, TJ ;
Meignier, B ;
Valentin, C ;
El Habib, R ;
Blondeau, C ;
Raux, M ;
Moog, C ;
Tartaglia, J ;
Chong, P ;
Klein, M ;
Milcamps, B ;
Heshmati, F ;
Plotkin, S .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1999, 15 (07) :633-645
[35]  
Sambrook J., 1989, MOL CLONING
[36]  
SIMON RD, 1981, J GEN MICROBIOL, V125, P103
[37]   Antigen presentation using novel particulate organelles from halophilic archaea [J].
Stuart, ES ;
Morshed, F ;
Sremac, M ;
DasSarma, S .
JOURNAL OF BIOTECHNOLOGY, 2001, 88 (02) :119-128
[38]  
THONGTHAI C, 1991, NATO ADV SCI I A-LIF, V201, P381
[39]   Tat-neutralizing antibodies in vaccinated macaques [J].
Tikhonov, I ;
Ruckwardt, TJ ;
Hatfield, GS ;
Pauza, CD .
JOURNAL OF VIROLOGY, 2003, 77 (05) :3157-3166
[40]   Immunization with recombinant p17/p24:Ty virus-like particles in human immunodeficiency virus-infected persons [J].
Veenstra, J ;
Williams, TG ;
Colebunders, R ;
Dorrell, L ;
Tchamouroff, SE ;
Patou, G ;
Lange, JMA ;
Weller, IVD ;
Goeman, J ;
Uthayakumar, S ;
Gow, IR ;
Weber, JN ;
Coutinho, RA .
JOURNAL OF INFECTIOUS DISEASES, 1996, 174 (04) :862-866